A gut feeling about murine syngeneic GVHD
J Scott Bryson1, J Anthony Brandon, C Darrell Jennings
1Division of Hematology and Blood & Marrow Transplantation, Department of Internal Medicine; University of Kentucky Medical Center, University of Kentucky, Lexington, KY USA.
Chimerism
|September 14, 2011
Summary
The gut microbiota and microbial immunity are crucial in developing murine syngeneic graft-versus-host disease (SGVHD). Antibiotic treatment significantly reduced SGVHD inflammation and pathology, highlighting the microbiota's role.
Area of Science:
- Immunology
- Microbiology
- Transplantation
Background:
- Murine syngeneic graft-versus-host disease (SGVHD) causes chronic inflammation in the colon and liver after bone marrow transplantation (BMT) and cyclosporine A (CsA) treatment.
- Previously attributed to autoreactive immune responses, SGVHD is now linked to enhanced antimicrobial immunity.
Purpose of the Study:
- To investigate the role of the gut microbiota in the development of murine SGVHD.
- To determine if microbial-specific immunity contributes to SGVHD pathogenesis.
Main Methods:
- Murine model of syngeneic graft-versus-host disease (SGVHD).
- Treatment with broad-spectrum antibiotics to deplete the gut microbiota.
- Analysis of inflammatory immune responses and pathology.
Main Results:
- Broad-spectrum antibiotics effectively eliminated disease-associated inflammatory immune responses in SGVHD mice.
- Antibiotic treatment significantly reduced SGVHD-related pathology.
- These findings implicate the microbiota and microbial immunity in SGVHD development.
Conclusions:
- The gut microbiota plays a critical role in the pathogenesis of murine SGVHD.
- Targeting the microbiota or microbial-specific immunity may offer therapeutic strategies for SGVHD.
- These findings suggest a re-evaluation of anti-microbial immune responses in post-transplant pathologies.
